Stock Taper
SCREENER COMPARE ANY 2 STOCKS
XENE
XENON PHARMACEUTICALS INC.
NASDAQ
$59.99
▼ DOWN 3.13% (-1.94)

KEY STATISTICS

Market Cap$5.80 B
52w High$72.66
52w Low$35.60
Dividend Yield—
Frequency—
P/E-12.76
Volume587.88K
Shares Out.96.67M

COMPANY

LEADERSHIP

Ian C. Mortimer
CHIEF EXECUTIVE
Ian C. Mortimer

COMPENSATION 2026

Salary$786,000
Stock Awards$1,774,000
Incentive Plan Pay$550,200
All Other Comp.$46,257
Total$9,221,712

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 5, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
364

PRICE TARGET

Target High$100.00
Target Low$69.00
Target Median$89.50
Target Consensus$86.50

UPCOMING EARNINGS

DateNov 2, 2026
DayMonday
Rev. Est.$1.33M
NOV
2
MON

PRICE

$59.99 ▼ DOWN 3.13% (−$1.94)
$60.00$60.50$61.00$61.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM59.99

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com ↗

Xenon Pharmaceuticals Inc., a Canadian clinical-stage biopharma, develops neurological therapeutics like Kv7 channel openers and sodium channel inhibitors, with multiple drugs in Phase II/III trials for epilepsy and related disorders.

INDUSTRY

Biotechnology

A PRODUCT XENON PHARMACEUTICALS INC. IS KNOWN FOR

Azetukalner
Azetukalner

Azetukalner is a potent Kv7 potassium channel opener in late-stage development, with Xenon’s lead drug candidate in Phase 3 trials for epilepsy, depression, and bipolar disorder.

COMPETITORS

COMPETITOR
BHVN COMPARE
NBIX COMPARE
PRAX COMPARE
RAPP COMPARE

Revenue by Products

IconPRODUCTQ4-2021Q1-2022Q2-2022Q3-2022
License And Service$9.01M $8.77M ▼$536K ▼$132K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
119
LISTED HERE
23
RANKED BY POSITION SIZE
IWM
0.19% · 2.5M
VTWO
0.19% · 550.9K
TCAF
0.39% · 524.3K
R2SC.L
0.19% · 180.5K
FESM
0.13% · 143.5K
SBIO
2.96% · 119.0K
XRSG.L
0.19% · 88.7K
NUSC
0.36% · 85.6K
GSC
1.03% · 47.0K
RSSL
0.19% · 46.9K
FSML
1.17% · 28.5K
WSCSRI.SW
0.19% · 25.1K
HRTS
0.89% · 8.3K
MMSC
0.81% · 6.9K
BBC
0.71% · 6.0K
IBBQ
0.38% · 6.0K
URTY
0.07% · 4.0K
ACSG
0.45% · 3.8K
MEDI
0.48% · 3.4K
SCDS
0.67% · 1.1K
ESLG
0.17% · 635
RESM
0.18% · 179
AVIE
0.06% · 115

INSTITUTIONAL OWNERSHIP

SHARES OWNED
59.85%
HOLDERS
381
TOP 12 OF 381 · RANKED BY POSITION SIZE
Fmr LLC
10.8M sh · $629.1M
Blackrock, Inc.
7.5M sh · $454.06M
Avoro Capital Advisors LLC
5.8M sh · $348.75M
Wellington Management Group Llp
4.8M sh · $280.84M
Polar Capital Holdings Plc
4.6M sh · $275.88M
Driehaus Capital Management LLC
4.5M sh · $203.42M
Janus Henderson Group Plc
4.2M sh · $242.86M
Braidwell LP
3.6M sh · $144.74M
Capital International Investors
3.4M sh · $153.06M
Price T Rowe Associates Inc /Md/
3.2M sh · $196.06M
Commodore Capital LP
2.7M sh · $108.41M
Citadel Advisors LLC
2.7M sh · $154.27M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
GANNON STEVEN
Sale · 10.0K shares
2026-08-11
★
DIRECTOR
Cannon Gillian
Sale · 1.2K shares
2026-06-05
★
DIRECTOR
PATOU GARY
Sale · 1.3K shares
2026-06-05
★
DIRECTOR
Machado Patrick
Purchase · 2.6K shares
2026-06-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OUTPERFORM 3
OVERWEIGHT 2
9 GRADES IN THE LAST 12 MONTHS
RBC Capital OUTPERFORM JP Morgan OVERWEIGHT Needham BUY Wedbush OUTPERFORM Wells Fargo OVERWEIGHT Deutsche Bank BUY HC Wainwright & Co. BUY Baird OUTPERFORM

SECTORS PEERS

PEERPRICE
APGE$134.97COMPARE
SRRK$57.80COMPARE
CGON$74.34COMPARE
TVTX$65.67COMPARE
CELC$88.44COMPARE
LEGN$19.88COMPARE
ZLAB$26.08COMPARE
RARE$25.61COMPARE